While early post-marketing reports suggested an increased risk of pancreatitis with incretin-based therapies, subsequent large-scale meta-analyses have not shown a statistically significant increase in pancreatitis incidence among GLP-1 receptor agonist users compared with other anti-diabetic agents [3-5]. The gene discussed is GLP1R; the disease is pancreatitis.